SCHEMBL4497778

SCHEMBL4497778

CN(C)CCN(C)C(=O)Cc1ccc(N)cc1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PHLPP2 Q6ZVD8 1/20 0.45
LTB4R Q15722 6/20 0.43
LTB4R2 Q9NPC1 6/20 0.43
SIGMAR1 Q99720 2/20 0.43
OPRK1 P41145 1/20 0.41
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA5A P35218 1/20 0.39
CA9 Q16790 1/20 0.39
CA5B Q9Y2D0 1/20 0.39
POLB P06746 1/20 0.39
APEX1 P27695 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4500145 0.90 PHLPP2 (0.43) PHLPP2LTB4RLTB4R2SIGMAR1OPRK1
SCHEMBL15652035 0.86 LTB4R (0.43) PHLPP2LTB4RLTB4R2SIGMAR1OPRK1
SCHEMBL17011380 0.82 OPRK1 (0.41) LTB4RLTB4R2SIGMAR1OPRK1POLB
SCHEMBL17011382 0.82 SIGMAR1 (0.46) PHLPP2LTB4RLTB4R2SIGMAR1OPRK1
SCHEMBL4052270 0.80 NUDT1 (0.49) PHLPP2OPRK1POLBAPEX1TDP1
SCHEMBL12460026 0.79 OPRK1 (0.44) LTB4RLTB4R2SIGMAR1OPRK1POLB
SCHEMBL18067945 0.78 LTB4R (0.39) PHLPP2LTB4RLTB4R2SIGMAR1OPRK1
SCHEMBL12460081 0.78 OPRK1 (0.43) LTB4RLTB4R2SIGMAR1OPRK1
SCHEMBL4481842 0.78 SIGMAR1 (0.66) SIGMAR1OPRK1POLBALDH1A1GAA
SCHEMBL8790187 0.77 LTB4R (0.59) LTB4RLTB4R2SIGMAR1ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed
EP-1527046-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-05-04 EP disclosed
WO-2004009546-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-01-29 WO disclosed
US-6586475-B1 5-chloro-N-(2-N,N-diethylamino)ethyl)-2- methoxy-4-(1-naphthoylamino)benzamide and prodrugs, used for prevention of neurodegenarative diseases such as Alzheimer's disease TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-07-01 US disclosed
EP-1132376-A1 BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS Takeda Chemical Industries, Ltd. (JP) 2001-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR PHLPP2 1485/4885LTB4R 1011/4885LTB4R2 1491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.